| Literature DB >> 30071893 |
Martijn de Roon1, Anne M May1, Anne McTiernan2,3, Rob J P M Scholten1,4, Petra H M Peeters1,5, Christine M Friedenreich6,7,8, Evelyn M Monninkhof9.
Abstract
BACKGROUND: Physical inactivity and being overweight are modifiable lifestyle risk factors that consistently have been associated with a higher risk of postmenopausal breast cancer in observational studies. One biologic hypothesis underlying this relationship may be via endogenous sex hormone levels. It is unclear if changes in dietary intake, physical activity, or both, are most effective in changing these hormone levels.Entities:
Keywords: Breast cancer; Caloric restriction; Exercise; Postmenopausal women; Prevention; Sex hormones; Weight loss
Mesh:
Substances:
Year: 2018 PMID: 30071893 PMCID: PMC6090977 DOI: 10.1186/s13058-018-1009-8
Source DB: PubMed Journal: Breast Cancer Res ISSN: 1465-5411 Impact factor: 6.466
Fig. 1Flow chart of the selection and inclusion of eligible studies
Characteristics of the six included studies
| Study | Study arms | Mean age (SD) (years) | Sample size, | Sex hormone outcomes | Methods for sex hormone evaluation | Intervention period |
|---|---|---|---|---|---|---|
| SHAPE-2 [ | Ex + D | 59.5 (4.9) | 98; 9 (9%) | Total estradiol, estrone, free estradiol, total testosterone, free testosterone, SHBG, androstenedione | Determined by liquid chromatography-mass spectrometry (LC-MC). SHBG by double-antibody radioimmunoassay (RIA) kitsb | 16 weeksa |
| D | 60.5 (4.6) | 97; 6 (6%) | ||||
| C | 60.0 (4.9) | 48; 3 (6%) | ||||
| NEW trial [ | Ex + D | 58.0 (4.4) | 117; 9 (8%) | Total estradiol, estrone, free estradiol, total testosterone, free testosterone, SHBG, androstenedione | Quantified by RIA after organic solvent extraction and Celite column partition chromatography. SHBG via chemiluminescent immunometric assay using Immulite Analyzerb | 6 months, 12 months |
| Ex | 58.1 (5.0) | 117; 11 (9%) | ||||
| D | 58.1 (5.9) | 118; 13 (11%) | ||||
| C | 57.4 (4.4) | 87; 7 (8%) | ||||
| ALPHA trial [ | Ex | 61.2 (5.4) | 160; 6 (4%) | Total estradiol, estrone, free estradiol, total testosterone, free testosterone, SHBG, androstenedione | Quantified by RIA after organic solvent extraction and Celite column partition chromatography. SHBG via immunometric assay using Immulite Analyzerb | 6 months, 12 months |
| C | 60.6 (5.7) | 160; 6 (4%) | ||||
| SHAPE-1, 2009 [ | Ex | 58.9 (4.6) | 96; 1 (1%) | Total estradiol, estrone, free estradiol, total testosterone, free testosterone, SHBG, androstenedione | Double-antibody RIA kits were used for determining sex hormones, also for SHBGb | 4 months, 12 months |
| C | 58.4 (4.2) | 93; 5 (5%) | ||||
| Orsatti et al. [ | Ex | 57.8 (8.0) | 27; 6 (22%) | Total testosterone, total estradiol | Measured by the Immulite System, automated immunoassay. | 16 weeks |
| C | 59.3 (6.2) | 23; 1 (4%) | ||||
| PATH trial [ | Ex | 60.7 (6.7) | 87; 3 (3%) | Total estradiol, estrone, free estradiol, total testosterone, free testosterone, SHBG, androstenedione | Quantified by RIA after organic solvent extraction and Celite column partition chromatography. SHBG via immunometric assay using Immulite Analyzerb | 12 months |
| C | 60.6 (6.8) | 86; 0 |
ALPHA Alberta Physical Activity and Breast Cancer, C control, D reduced calorie diet, Ex exercise, NEW Nutrition and Exercise for Woman, PATH Physical Activity for Total Health, SHAPE Sex Hormone and Physical Exercise, SHBG sex hormone binding globulin
aAlthough this study took 16 weeks, results were pooled with the other studies
bFree estradiol/free testosterone were calculated using the measured values for estradiol, testosterone, and SHBG, and assumed constant for albumin
Intervention characteristics of included studies
| Study | Intervention | Start intervention | Duration of program | Frequency and duration of sessions | Intensity | Adherence | Control group |
|---|---|---|---|---|---|---|---|
| SHAPE-2 [ | Ex + D | 4–6 week run-in period. Standardized diet to maintain stable weight and to achieve a comparable diet composition among all participants | 4–6 run period + 16 week intervention | 4 h/week, two 1-h group sessions of combined strength and endurance, two 1-h sessions of Nordic walking | 20–25 min of endurance training (60–90% of HRR), 25 min strength training, 5–10 min WU/CD, caloric restriction was 1750 kcal/week. Moderate to vigorous Nordic walking (60–65% of HRR) | Group sessions were supervised. Participants kept an exercise log that the physiotherapist regularly checked | The control group was asked to maintain a stable weight by continuing the standardized diet and their habitual physical activity patterns. After study completion the control group was offered a weight loss intervention |
| NEW trial [ | Ex | A 10% reduction in body weight at 6 months with maintenance thereafter to 12 months | 5 days/225 min per week for 12 months. | Exercise started with a 15 min session at 60–70% of MHR and progressed to 70–85% of MHR for 45 min by the 7th week where it was maintained for the rest of the study. | Participants attended at least three supervised sessions per week. In home sessions they recorded mode and duration of the exercise. Women were asked to record all food eaten daily for at least 6 months. Journaling, weekly weighing, and sessions attendance were tracked to promote adherence | The control group was asked not to change their diet or exercise habits. After study completion the control group was offered a weight loss intervention | |
| ALPHA trial [ | Ex | Started with three sessions per week of 15 to 20 min | During the first 3 months the frequency, duration and intensity increased and maintained for 9 more months | 5 days per week of at least 45 min of aerobic exercise | During the first 3 months frequency, duration and intensity were increased from three sessions a week of 15 to 20 min in duration at an intensity of 50 to 60% of HRR to five sessions per week of at least 45 min at 70–80% of HRR | Three sessions per week were facility based. Adherence was monitored through weekly participant- and trainer- administered exercise logs | Controls were asked to maintain their inactive lifestyle. All participants were instructed not to change their usual diet |
| SHAPE-1 [ | Ex | 12 months | Twice per week a 1-h exercise intervention, once per week home-based exercise | 10 min WU, 25 min moderate to vigorous aerobic exercise at 60–85% of MHR, 25 min strength training, 5 min CD. Home-based exercise session contained 30 min of brisk walking or cycling with an intensity of moderate to vigorous intensity (60–80% of MHR) | Sport instructors register the attendance of the subjects. Study coordinator performed visits per exercise group to control adherence of the protocol | Controls were requested to retain their habitual exercise pattern | |
| Orsatti et al. [ | Ex | Before training, subjects in the exercise group attended a 4-week adaptation period to become familiarized with the protocol | 16 weeks | 3 weekly session on nonconsecutive days, under supervision. | Initially lighter loads were used and subjects performed 1 set of 15 repetitions at 40–50% of 1-RM, progression was gradual till 3 sets of 8–12 repetitions at 60–80% of 1-RM were performed. Protocol consisted of dynamic exercises for both lower and upper limbs for a total of 50–60 min. Loads were periodically adjusted at the end of each month | Attendance was recorded by the trainers | Controls were advised to keep their habitual diets and asked not to change their exercise habits |
| PATH trial [ | Ex | 12 months | At least 45 min of moderate-intensity exercise, 5 days/week for 12 months | The training program started at 40% of observed MHR for 16 min/session and gradually increased to 60–75% of MHR for 45 min/session by week 8 | Participants were required to attend the three offered supervised sessions/week during months 1–3 and to exercise on 2 days/week at home. For months 4–12, they were required to attend at least one of the three offered sessions/week at a study facility and to exercise 4 days per week at home or at the facility | Control participants attended 1 weekly 45-min stretching session for 12 months and were asked not to change other exercise habits. Both groups were asked to maintain their usual diet |
1-RM one-repetition maximum, ALPHA Alberta Physical Activity and Breast Cancer, CD cooling down, D reduced calorie diet, Ex exercise, HRR heart rate reserve, MHR maximal heart rate, NEW Nutrition and Exercise for Woman, PATH Physical Activity for Total Health, SHAPE Sex Hormone and Physical Exercise, WU warming-up
Effect of the interventions on body weight and on serum sex hormones levels
| Name, duration | Baseline valuea | Postinterventiona | Within-group difference (%) | Between-group differenceb | Between-group differenceb |
|---|---|---|---|---|---|
| Weight (kg) or BMIc | |||||
| SHAPE-2 [ | |||||
| Exercise + diet (Ex+WL) | 80.4 | 74.9 | −5.5 | −5.58 (−6.32 to −4.84) | Ex+WL vs WL |
| Reduced calorie diet (WL) | 80.3 | 75.4 | −4.9 | − 4.95 (−5.69 to −4.21) | −0.63 (−1.23 to −0.04) |
| Control | 80.4 | 80.4 | 0.1 | Referent | |
| NEW trial [ | |||||
| Exercise + diet | 82.5 | 72.7 | −9.8 | Ex+WL vs WL, | |
| Exercise | 83.7 | 80.9 | −2.8 | Ex+WL vs Ex, | |
| Reduced calorie diet | 84.0 | 74.9 | −9.1 | Ex vs WL, | |
| Control | 84.2 | 83.7 | −0.5 | Referent | |
| ALPHA trial [ | |||||
| Exercise | −2.3 | −1.80 (−2.60 to −1.00) | |||
| Control | −0.5 | Referent | |||
| SHAPE-1 [ | |||||
| Exercise | 73.6 | 72.2 | −1.4 | N/A | |
| Control | 74.8 | 74.0 | −0.8 | ||
| Orsatti et al. [ | |||||
| Exercise | 28.8c | 29.6c | 0.6c | ||
| Control | 27.6c | 27.1c | −0.5c | Referent | |
| PATH trial [ | |||||
| Exercise | 81.6 | 80.3 | −1.6 | ||
| Control | 81.7 | 81.8 | 0.1 | Referent | |
| Total estradiol (pg/ml) | |||||
| SHAPE-2 [ | |||||
| Exercise + diet | 3.69 | 3.22 | −12.7 | 0.83 (0.73–0.95) | Ex+WL vs WL |
| Reduced calorie diet | 4.20 | 3.62 | −13.8 | 0.86 (0.75–0.98) | 0.97 (0.87–1.08) |
| Control | 3.89 | 4.01 | 3.11 | Referent | |
| NEW trial [ | |||||
| Exercise + diet | 11.5 | 9.2 | −20.3 | Ex+WL vs WL, | |
| Exercise | 11.5 | 11.0 | −4.9 | Ex+WL vs Ex, | |
| Reduced calorie diet | 11.6 | 9.7 | −16.2 | Ex vs WL, | |
| Control | 10.9 | 11.4 | 4.9 | Referent | |
| ALPHA trial [ | |||||
| Exercise | 10.1 | 8.7 | 0.93 (0.88–0.98) | ||
| Control | 10.2 | 9.9 | Referent | ||
| SHAPE-1 [ | |||||
| Exercise | 8.8 | 8.1 | −7.3 | 0.99 (0.95–1.02) | |
| Control | 9.8 | 8.8 | −10.2 | Referent | |
| Orsatti et al. [ | |||||
| Exercise | 21.5 | 23.2 | |||
| Control | 25.1 | 27.4 | Referent | ||
| PATH trial [ | |||||
| Exercise | 18.3 | 17.5 | −4.4 | ||
| Control | 17.9 | 17.8 | −0.6 | Referent | |
| Estrone (pg/ml) | |||||
| SHAPE-2 [ | |||||
| Exercise + diet | 19.9 | 18.5 | −6.67 | 0.92 (0.82:1.02) | Ex+WL vs WL |
| Reduced calorie diet | 20.4 | 20.1 | −1.26 | 0.98 (0.88:1.08) | 0.94 (0.86:1.02) |
| Control | 20.1 | 20.4 | 3.11 | Referent | |
| NEW trial [ | |||||
| Exercise + diet | 33.9 | 30.2 | −11.1 | Ex+WL vs WL, | |
| Exercise | 34.8 | 32.9 | −5.5 | Ex+WL vs Ex, | |
| Reduced calorie diet | 35.2 | 31.8 | −9.6 | Ex vs WL, | |
| Control | 32.0 | 34.6 | 8.1 | Referent | |
| ALPHA trial [ | 31.4 | 29.4 | |||
| Exercise | 31.3 | 30.6 | 0.99 (0.94–1.03) | ||
| Control | Referent | ||||
| SHAPE-1 [ | |||||
| Exercise | 30.6 | 27.6 | −9.7 | 0.97 (0.92–1.04) | |
| Control | 28.0 | 27.3 | −3.4 | Referent | |
| PATH trial [ | |||||
| Exercise | 44.2 | 42.5 | −1.8 | ||
| Control | 43.9 | 45.4 | 3.9 | Referent | |
| Free estradiol (pg/ml) | |||||
| SHAPE-2 [ | |||||
| Exercise + diet | 0.09 | 0.07 | −19.1 | 0.77 (0.67–0.88) | Ex+WL vs WL |
| Reduced calorie diet | 0.10 | 0.08 | −17.7 | 0.80 (0.70–0.92) | 0.96 (0.85–1.02) |
| Control | 0.09 | 0.10 | 3.23 | Referent | |
| NEW trial [ | |||||
| Exercise + diet | 0.32 | 0.23 | −26 | Ex+WL vs WL, | |
| Exercise | 0.30 | 0.29 | −4.7 | Ex+WL vs Ex, | |
| Reduced calorie diet | 0.31 | 0.24 | −21.4 | Ex vs WL, | |
| Control | 0.30 | 0.33 | 6.3 | Referent | |
| ALPHA trial [ | |||||
| Exercise | 0.24 | 0.21 | 0.91 (0.87–0.96) | ||
| Control | 0.25 | 0.24 | Referent | ||
| SHAPE-1 [ | |||||
| Exercise | 0.22 | 0.21 | −7.3 | 1.00 (0.96–1.04) | |
| Control | 0.25 | 0.23 | −10.2 | Referent | |
| PATH trial [ | |||||
| Exercise | 0.49 | 0.46 | −6.2 | ||
| Control | 0.47 | 0.47 | 0.0 | Referent | |
| Testosterone (pg/ml) | |||||
| SHAPE-2 [ | |||||
| Exercise + diet | 186 | 172 | −7.63 | 0.96 (0.87–1.05) | Ex+WL vs WL |
| Reduced calorie diet | 197 | 189 | −3.76 | 1.01 (0.92–1.10) | 0.95 (0.88–1.02)) |
| Control | 194 | 186 | 4.07 | Referent | |
| NEW trial [ | |||||
| Exercise + diet | 239 | 225 | −5.9 | Ex+WL vs WL, | |
| Exercise | 248 | 236 | −4.9 | Ex+WL vs Ex, | |
| Reduced calorie diet | 239 | 236 | −0.9 | Ex vs WL, | |
| Control | 228 | 232 | 1.8 | Referent | |
| ALPHA trial [ | |||||
| Exercise | 239 | 234 | 0.99 (0.95–1.03) | ||
| Control | 231 | 237 | Referent | ||
| SHAPE-1 [ | |||||
| Exercise | 528 | 507 | −4.0 | 0.98 (0.94–1.01) | |
| Control | 535 | 526 | −1.6 | Referent | |
| PATH trial [ | |||||
| Exercise | 211 | 208 | |||
| Control | 223 | 218 | Referent | ||
| Androstenedione (pg/ml) | |||||
| SHAPE-2 [ | |||||
| Exercise + diet | 573 | 488 | −14.7 | 0.87 (0.76–1.00) | Ex+WL vs WL |
| Reduced calorie diet | 562 | 537 | −4.5 | 0.97 (0.85–1.12) | 0.90 (0.80–1.01) |
| Control | 575 | 560 | −2.6 | Referent | |
| NEW trial [ | |||||
| Exercise + diet | 526 | 508 | −3.5 | Ex+WL vs WL, | |
| Exercise | 502 | 496 | −1.2 | Ex+WL vs Ex, | |
| Reduced calorie diet | 511 | 518 | 1.4 | Ex vs WL, | |
| Control | 487 | 494 | 1.5 | Referent | |
| ALPHA trial [ | |||||
| Exercise | 578 | 572 | 0.98 (0.93–1.03) | ||
| Control | 553 | 577 | Referent | ||
| SHAPE-1 [ | |||||
| Exercise | 1146 | 1115 | −2.7 | 0.97 (0.93–1.01) | |
| Control | 1172 | 1199 | 2.3 | Referent | |
| PATH trial [ | |||||
| Exercise | 533 | 480 | |||
| Control | 585 | 525 | Referent | ||
| Free testosterone (pg/ml) | |||||
| SHAPE-2 [ | |||||
| Exercise + diet | 2.44 | 2.01 | −17.7 | 0.84 (0.76–0.93) | Ex+WL vs WL |
| Reduced calorie diet | 2.53 | 2.25 | −11.2 | 0.91 (0.83–1.01) | 0.92 (0.85–0.99) |
| Control | 2.71 | 2.61 | −3.9 | Referent | |
| NEW trial [ | |||||
| Exercise + diet | 5.3 | 4.5 | −15.6 | Ex+WL vs WL, | |
| Exercise | 5.1 | 4.9 | −4.5 | Ex+WL vs Ex, | |
| Reduced calorie diet | 5.1 | 4.6 | −10.0 | Ex vs WL, | |
| Control | 4.9 | 5.1 | 2.6 | Referent | |
| ALPHA trial [ | |||||
| Exercise | 3.5 | 3.3 | 0.96 (0.92–1.01) | ||
| Control | 3.5 | 3.5 | Referent | ||
| SHAPE-1 [ | |||||
| Exercise | 8.7 | 8.5 | −2.9 | 0.99 (0.95–1.03) | |
| Control | 8.7 | 8.5 | −1.8 | Referent | |
| PATH trial [ | |||||
| Exercise | 4.6 | 4.3 | |||
| Control | 4.7 | 4.6 | Referent | ||
| SHBG (nmol/l) | |||||
| SHAPE-2 [ | |||||
| Exercise + diet | 49.3 | 58.6 | 19.0 | 1.21 (1.12–1.30) | Ex+WL vs WL |
| Reduced calorie diet | 50.7 | 57.1 | 12.6 | 1.14 (1.07–1.23) | 1.05 (1.00–1.12) |
| Control | 44.2 | 44.0 | −0.30 | Referent | |
| NEW trial [ | |||||
| Exercise + diet | 34.1 | 42.9 | 25.8 | Ex+WL vs WL, | |
| Exercise | 39.1 | 38.8 | 0.7 | Ex+WL, vs Ex | |
| Reduced calorie diet | 35.8 | 43.8 | 22.4 | Ex vs WL, | |
| Control | 34.7 | 33.7 | −2.7 | Referent | |
| ALPHA trial [ | |||||
| Exercise | 40.3 | 41.9 | 1.04 (1.02–1.07) | ||
| Control | 38.1 | 38.4 | Referent | ||
| SHAPE-1 [ | |||||
| Exercise | 33.9 | 33.6 | −0.7 | 0.98 (0.92–1.04) | |
| Control | 34.7 | 33.6 | −3.3 | Referent | |
| PATH trial [ | |||||
| Exercise | 35.2 | 38.3 | 8.8 | ||
| Control | 35.8 | 36.7 | 2.5 | Referent | |
ALPHA Alberta Physical Activity and Breast Cancer, NEW Nutrition and Exercise for Woman, PATH Physical Activity for Total Health, SHAPE Sex Hormone and Physical Exercise, SHBG sex hormone binding globulin
aGeometric means reported
bValues are given as either treatment effect ratios (95% confidence intervals) or as P values
cBody mass index (BMI) was reported when bodyweight was not available
Pooled mean differences of the four comparisons on the different sex hormone outcomes and sex hormone binding globulin (SHBG)
| Pooled effectsa | Treatment effect ratios (95% confidence interval) |
|---|---|
| Estrone | |
| Exercise vs control | 0.97 (0.94–1.01) |
| Exercise + diet vs control | 0.90 (0.83–0.97) |
| Diet vs control | 0.95 (0.88–1.03) |
| Exercise + diet vs diet | 0.94 (0.88–1.01) |
| Total estradiol | |
| Exercise vs control | 0.97 (0.94–1.00) |
| Exercise + diet vs control | 0.82 (0.75–0.90) |
| Diet vs control | 0.86 (0.77–0.95) |
| Exercise + diet vs diet | 0.96 (0.89–1.04) |
| Free estradiol | |
| Exercise vs control | 0.95 (0.87–1.01) |
| Exercise + diet vs control | 0.73 (0.66–0.81) |
| Diet vs control | 0.77 (0.69–0.84) |
| Exercise + diet vs diet | 0.96 (0.87–1.06) |
| Total testosterone | |
| Exercise vs control | 0.98 (0.95–1.01) |
| Exercise + diet vs control | 0.96 (0.89–1.04) |
| Diet vs control | 1.01 (0.94–1.09) |
| Exercise + diet vs diet | 0.95 (0.89–1.01) |
| Free testosterone | |
| Exercise vs control | 0.97 (0.95–1.00) |
| Exercise + diet vs control | 0.86 (0.79–0.93) |
| Diet vs control | 0.91 (0.84–0.98) |
| Exercise + diet vs diet | 0.94 (0.88–1.00) |
| Androstenedione | |
| Exercise vs control | 0.97 (0.94–1.00) |
| Exercise + diet vs control | 0.95 (0.80–1.12) |
| Diet vs control | 1.01 (0.93–1.11) |
| Exercise + diet vs diet | 0.94 (0.87–1.02) |
| SHBG | |
| Exercise vs control | 1.03 (0.99–1.08) |
| Exercise + diet vs control | 1.23 (1.15–1.31) |
| Diet vs control | 1.20 (1.06–1.36) |
| Exercise + diet vs diet | 1.03 (0.97–1.09) |
a For readability reduced calorie diet is labeled as “diet”
Fig. 2Forest plots per sex hormone. Plots per comparison: 1) exercise compared with control; 2) exercise (Ex) and diet (WL) versus control; 3) diet (WL) versus control; 4) exercise (Ex) and diet (WL) versus diet (WL). ALPHA Alberta Physical Activity and Breast Cancer, CI confidence interval, NEW Nutrition and Exercise for Woman, PATH Physical Activity for Total Health, SHAPE Sex Hormone and Physical Exercise, TER treatment effect ratio